TQB-3804 (TQB3804; EGFR-IN-7; compound 34) is a 4th-generation, oralli bioactive and selective EGFR kinase inhibitor (EGFR-TKI, developed in China and disclosed in patent WO2019015655A1) with potential anticancer activity. It inhibits EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50s of 7.92 nM and 0.218 nM, respectively.

纯度：≥98%

CAS：2267329-76-8